- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04260438
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
An Open-label, Randomized, Fed, Single Dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
Study Overview
Status
Conditions
Detailed Description
To healthy subjects of twenty-four (24), following treatments are administered dosing in each period and wash-out period is a minimum of 7 days.
Reference drug: 1) CKD-501 0.5mg 2) D759 3) D150 Test drug: 1) CKD-393 0.5/100/1000mg formulation Ⅰ Tab. 2) CKD-393 0.5/100/1000mg formulation Ⅱ Tab.
Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are assessed.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Korea University Anam Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male volunteers, aged between ≥ 19 and ≤ 55 years old at the time of screening.
Weight ≥ 50kg, with calculated body mass index (BMI) of ≥ 18.5 and ≤ 29.9 kg/m2
* BMI = Weight(kg)/ Height(m)2
- Subject who consents to use at least two clinically effective birth controls for at least 1 month following the last dose.
- Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and comply with the relevant instructions in written.
Exclusion Criteria:
- History or presence of clinically significant and sever active cardiovascular, respiratory, hepatobiliary, renal, endocrine, hematological, gastrointestinal, neurologic, immune, dermatologic or psychiatric disorder.
- With symptoms indicating acute illness within 28 days prior to the first Investigational Product (IP) administration.
- Any medical history that may affect drug absorption, distribution, metabolism and excretion.
Individuals who had history of hypersensitivity to follow drugs, derivative drugs or others drugs(aspirin and antibiotics etc.) or had history of drug abuse
- Thiazolidinedione
- DPP-4 inhibitor
- Metformin
- Any clinically significant chronic medical illness.
- Any genetic disease including galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Individuals with one of the following laboratory test results in screening
- AST, ALT > UNL (upper normal limit) x 3
- fasting glucose < 70 mg/dL or > 125 mg/dL
- Creatinine clearance ≤ 80 mL/min
- In ECG result, QTc > 450 msec
- hCG(+) (only women)
- Individuals who had positive test results at HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL.
- Use of any prescription drugs within 14 days prior to study drug administration.
- Use of over-the-counter medications and herbal preparations within 7 days prior to study drug administration.
- History of any clinically significant allergic reaction (However, mild allergic rhinitis or allergic dermatitis which do not required medication may be allowed).
- Individuals who cannot eat standard meal provided from clinical trial center.
- Donation of blood within 60 days prior to study drug administration or apheresis within 20 days prior to the first IP administration.
- Individuals who had received a blood transfusion within 30 days prior to study drug administration.
- Exposure to any investigational drug within 6 months prior to the first IP administration.
- Individuals taking any drugs inducing or inhibiting drug metabolizing enzymes including barbiturates within 30 days prior to the first IP administration.
- Individuals who had consumed grapefruit juice > 5cups/day or caffeine > 5cups/day within 30 days prior to the first IP administration or who cannot stopping consume grapefruit juice or caffeine during clinical study.
- Individuals who had drinking (alcohol > 30 g/day) within 30 days prior to the first IP administration or who cannot stopping drink.
- Heavy smoking (more than 10 cigarettes/day) within 30 days prior to screening or who cannot quit smoking during clinical study.
- Pregnant or women who may be pregnant
- Subjects having been deemed inappropriate for the trial as determined by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
Experimental: Group 2
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
Experimental: Group 3
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
Experimental: Group 4
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
Experimental: Group 5
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
Experimental: Group 6
|
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
single oral administration under fed condition
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCt of CKD-501, D759, D150, CKD-393
Time Frame: Time Frame: 0 hour ~ 48 hours
|
Area under the CKD-501/D759/D150/CKD-393 concentration in blood-time curve from zero to final
|
Time Frame: 0 hour ~ 48 hours
|
Cmax of CKD-501, D759, D150, CKD-393
Time Frame: Time Frame: 0 hour ~ 48 hours
|
The maximum CKD-501/D759/D150/CKD-393 concentration in blood sampling time t
|
Time Frame: 0 hour ~ 48 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A98_01BE1922P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
-
Chong Kun Dang PharmaceuticalCompletedHypertension | DyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownHypertensionKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of